Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Macular Edema After Retinal Vein Occlusion (MK-8748-006)

16. november 2026 oppdatert av: Merck Sharp & Dohme LLC

Randomized, Double-Masked, Multicenter, 3 Arm, Pivotal Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal (IVT) MK-8748 Compared With Aflibercept (2 mg) in Participants With Macular Edema Following Retinal Vein Occlusion (ME-RVO)

Researchers are looking for new ways to treat macular edema after retinal vein occlusion (ME-RVO). ME-RVO happens when a vein becomes blocked in the retina, the back part of the eye. This blockage causes fluid to leak into the macula, which is the part of the retina that helps to see fine details. The buildup of fluid, called macular edema, can cause blurry vision.

In this trial, researchers want to learn if a trial medicine called MK-8748 can treat ME-RVO. A standard (usual) treatment for ME-RVO is aflibercept. However, standard treatments such as aflibercept may not work for every person.

The main goal of this trial is to learn if participants who receive MK-8748 can see as clearly as participants who receive aflibercept.

Studieoversikt

Status

Har ikke rekruttert ennå

Studietype

Intervensjonell

Registrering (Antatt)

1188

Fase

  • Fase 2
  • Fase 3

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

The main inclusion criteria include but are not limited to the following:

  • Has a diagnosis of macular edema following retinal vein occlusion (ME-RVO) within 4 months (120 days) before screening and is treatment-naïve for ME-RVO
  • Has a BCVA ETDRS letter score between 73 and 19 (20/40 - 20/400 Snellen equivalent), inclusive, in the study eye at screening. In the event that both eyes are eligible, the worst-seeing eye should be enrolled in the trial.
  • Has a decrease in vision in the study eye determined by the investigator to be primarily the result of ME-RVO.

The main exclusion criteria include but are not limited to the following:

  • Has history of stroke (cerebral vascular accident) or myocardial infarction within 180 days prior to study entry
  • Has any active malignancy, except non-melanoma skin carcinoma.
  • Has history of previous episodes of ME-RVO or persistent ME-RVO diagnosed more than 4 months before screening
  • Has any prior steroid implant use including dexamethasone intravitreal implant (Ozurdex®) and fluocinolone acetonide intravitreal implant (Iluvien®) or other intraocular or periocular corticosteroids in the study eye at any time.
  • Has prior periocular pharmacological or intravitreal treatment (including anti-vascular endothelial growth factor medication) for other retinal diseases in the study eye at any time.
  • Has a history of cataract surgery and/or minimally invasive glaucoma surgery in the study eye within 90 days of screening.
  • Has significant active retinal disease (ie, moderate non-proliferative diabetic retinopathy or worse, proliferative diabetic retinopathy, geographic atrophy, myopic choroidal neovascularization) other than the ME-RVO under investigation in the study eye.
  • Is currently using drugs with known retinal toxicity (eg, hydroxychloroquine, pentosan polysulfate sodium).

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Trippel

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: MK-8748 low dose

Participants receive MK-8748 low dose every 4 weeks (Q4W) administered in the study eye until week 48. After week 48, participants will be treated at intervals determined based on individualized response to treatment, up to week 96.

Administered via intravitreal (IVT) injection

Andre navn:
  • EYE201
Eksperimentell: MK-8748 High Dose

Participants receive MK-8748 high dose every 4 weeks (Q4W) administered in the study eye until week 48. After week 48, participants will be treated at intervals determined based on individualized response to treatment, up to week 96.

Administered via intravitreal (IVT) injection

Andre navn:
  • EYE201
Aktiv komparator: Aflibercept 2 mg

Participants receive aflibercept 2 mg every 4 weeks (Q4W) administered in the study eye until week 48. After week 48, participants will be treated at intervals determined based on individualized response to treatment, up to week 96.

Administered via IVT injection

Andre navn:
  • EYLEA

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Mean Change in Best-Corrected Visual Acuity (BCVA) (Early Treatment of Diabetic Retinopathy Study [ETDRS] Letters) From Baseline to Week 24
Tidsramme: Baseline and Week 24

Participants' BCVA in the study eye will be measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. Mean change in ETDRS letters from baseline to week 24 will be assessed.

Baseline and Week 24

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Mean Change in Central Subfield Thickness (CST) from Baseline to Week 24
Tidsramme: Baseline and Week 24

Central subfield thickness (CST) in the study eye will be measured in microns using optical coherence tomography (OCT). The mean change in CST from baseline to week 24 will be presented.

Baseline and Week 24
Mean Change in CST from Baseline Over Time
Tidsramme: Up to approximately 96 weeks

Central subfield thickness (CST) in the study eye will be measured in microns using optical coherence tomography (OCT). The mean change in CST from baseline over time will be presented.

Up to approximately 96 weeks
Time to Absence of Diabetic Macular Edema (DME)
Tidsramme: Up to approximately 96 weeks

The absence of Diabetic Macular Edema (DME) is defined as a Central Subfield Thickness (CST) of <300 μm measured using optical coherence tomography (OCT). The time to absence of Diabetic Macular Edema (DME) in the study eye will be presented.

Up to approximately 96 weeks
Proportion of Participants with Absence of Intraretinal Fluid Over Time
Tidsramme: Up to approximately 96 weeks

Participants' intraretinal fluid in the study eye will be measured using optical coherence tomography (OCT). The proportion of participants with absence of intraretinal fluid over time will be presented.

Up to approximately 96 weeks
Proportion of Participants with Absence of Subretinal Fluid Over Time
Tidsramme: Up to approximately 96 weeks

Participants' subretinal fluid in the study eye will be measured using optical coherence tomography (OCT). The proportion of participants with absence of subretinal fluid over time will be presented.

Up to approximately 96 weeks
Proportion of Participants with Absence of Intraretinal Fluid and Subretinal Fluid Over Time
Tidsramme: Up to approximately 96 weeks

Participants' subretinal fluid and intraretinal fluid in the study eye will be measured using optical coherence tomography (OCT). The proportion of participants with absence of intraretinal and subretinal fluid over time will be presented.

Up to approximately 96 weeks
Proportion of Participants with Resolution of Macular Leakage on Fluorescein Angiography (FA) at Week 24
Tidsramme: Week 24

Fluorescein Angiography (FA) images will be used to determine the resolution of macular leakage in the study eye, defined as 0 to 1 mm^2. The proportion of participants with resolution of macular leakage at Week 24 will be presented.

Week 24
Proportion of Participants with Resolution of Macular Leakage on FA at Week 48
Tidsramme: Week 48

FA images will be used to determine the resolution of macular leakage in the study eye, defined as 0 to 1 mm^2. The proportion of participants with resolution of macular leakage at Week 48 will be presented.

Week 48
Proportion of Participants with Resolution of Macular Leakage on FA at Week 96
Tidsramme: Week 96

FA images will be used to determine the resolution of macular leakage in the study eye, defined as 0 to 1 mm^2. The proportion of participants with resolution of macular leakage at Week 96 will be presented.

Week 96
Mean Change in Vascular Leakage Area on FA in the Macula From Baseline Over Time
Tidsramme: Up to approximately 96 weeks

Vascular leakage area in the macula will be evaluated using FA images graded by a centralized reading center. The total area of macular vascular leakage will be measured in square millimeters (mm²). The mean change in vascular leakage area from baseline over time will be presented.

Up to approximately 96 weeks
Mean Change From Baseline in Macular Ischemic Nonperfusion Area as Assessed by Optical Coherence Tomography Angiography (OCT-A)
Tidsramme: Up to approximately 96 weeks

Macular ischemic nonperfusion area (defined as areas of capillary nonperfusion or capillary drop-out within the superficial and/or deep retinal capillary plexuses) is measured in square millimeters (mm²) using OCT-A. Images are analyzed and graded by a centralized, masked independent reading center. The mean change in ischemic nonperfusion area from baseline over time will be presented.

Up to approximately 96 weeks
Proportion of Participants Requiring Panretinal Photocoagulation
Tidsramme: Up to approximately 96 weeks

The proportion of participants requiring panretinal photocoagulation treatment will be presented.

Up to approximately 96 weeks
Mean Number of Intravitreal (IVT) Injections from Week 48 to Week 96
Tidsramme: Up to approximately 48 weeks

The mean number of intravitreal (IVT) Injections from week 48 to week 96 will be presented.

Up to approximately 48 weeks
Proportion of Participants on a Personalized Treatment Interval (PTI) of Every 4 Weeks (Q4W) at Week 96
Tidsramme: Up to approximately 96 weeks

The proportion of participants on a personalized treatment interval (PTI) of Q4W at Week 96 will be presented.

Up to approximately 96 weeks
Proportion of Participants on a Personalized Treatment Interval (PTI) of Every 8 Weeks (Q8W) at Week 96
Tidsramme: Up to approximately 96 weeks

The proportion of participants on a personalized treatment interval (PTI) of Q8W at Week 96 will be presented.

Up to approximately 96 weeks
Proportion of Participants on a Personalized Treatment Interval (PTI) of Every 12 Weeks (Q12W) at Week 96
Tidsramme: Up to approximately 96 weeks

The proportion of participants on a personalized treatment interval (PTI) of Q12W at Week 96 will be presented.

Up to approximately 96 weeks
Proportion of Participants on a Personalized Treatment Interval (PTI) of Every 16 Weeks (Q8W) at Week 96
Tidsramme: Up to approximately 96 weeks

The proportion of participants on a personalized treatment interval (PTI) of Q16W at Week 96 will be presented.

Up to approximately 96 weeks
Mean Change in BCVA (ETDRS letters) from Baseline Over Time
Tidsramme: Baseline and 96 weeks

Participants' BCVA in the study eye will be measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The mean change in BCVA (ETDRS) letters from baseline over time will be presented.

Baseline and 96 weeks
Proportion of Participants who Gain ≥5 ETDRS Letters from Baseline at Week 24
Tidsramme: Baseline and week 24

Participants' BCVA in the study eye will be measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The proportion of participants who gain ≥5 ETDRS letters from baseline to year 1 will be presented.

Baseline and week 24
Proportion of Participants who Gain ≥10 ETDRS Letters from Baseline at Week 24
Tidsramme: Baseline and week 24

Participants' BCVA in the study eye will be measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The proportion of participants who gain ≥10 ETDRS letters from baseline to year 1 will be presented.

Baseline and week 24
Proportion of Participants who Gain ≥15 ETDRS Letters from Baseline at Week 24
Tidsramme: Baseline and week 24

Participants' BCVA in the study eye will be measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The proportion of participants who gain ≥15 ETDRS letters from baseline to year 1 will be presented.

Baseline and week 24
Proportion of Participants who Gain ≥5 ETDRS Letters from Baseline Over Time
Tidsramme: Up to approximately 96 weeks

Participants' BCVA in the study eye will be measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The proportion of participants who gain ≥5 ETDRS letters from baseline over time will be presented.

Up to approximately 96 weeks
Proportion of Participants who Gain ≥10 ETDRS Letters from Baseline Over Time
Tidsramme: Up to approximately 96 weeks

Participants' BCVA in the study eye will be measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The proportion of participants who gain ≥10 ETDRS letters from baseline over time will be presented.

Up to approximately 96 weeks
Proportion of Participants who Gain ≥15 ETDRS Letters from Baseline Over Time
Tidsramme: Up to approximately 96 weeks

Participants' BCVA in the study eye will be measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The proportion of participants who gain ≥15 ETDRS letters from baseline over time will be presented.

Up to approximately 96 weeks
Proportion of Participants who Lose ≥5 ETDRS Letters from Baseline at Week 24
Tidsramme: Baseline and Week 24

Participants' BCVA in the study eye will be measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The proportion of participants who lose ≥5 ETDRS letters from baseline to week 24 will be presented.

Baseline and Week 24
Proportion of Participants who Lose ≥10 ETDRS Letters from Baseline at Week 24
Tidsramme: Baseline and Week 24

Participants' BCVA in the study eye will be measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The proportion of participants who lose ≥10 ETDRS letters from baseline to week 24 will be presented.

Baseline and Week 24
Proportion of Participants who Lose ≥15 ETDRS Letters from Baseline at Week 24
Tidsramme: Baseline and Week 24

Participants' BCVA in the study eye will be measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The proportion of participants who lose ≥15 ETDRS letters from baseline to week 24 will be presented.

Baseline and Week 24
Proportion of Participants who Lose ≥5 ETDRS Letters from Baseline Over Time
Tidsramme: Up to approximately 96 weeks

Participants' BCVA in the study eye will be measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The proportion of participants who lose ≥5 ETDRS letters from baseline over time will be presented.

Up to approximately 96 weeks
Proportion of Participants who Lose ≥10 ETDRS Letters from Baseline Over Time
Tidsramme: Up to approximately 96 weeks

Participants' BCVA in the study eye will be measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The proportion of participants who lose ≥10 ETDRS letters from baseline over time will be presented.

Up to approximately 96 weeks
Proportion of Participants who Lose ≥15 ETDRS Letters from Baseline Over Time
Tidsramme: Up to approximately 96 weeks

Participants' BCVA in the study eye will be measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The proportion of participants who lose ≥15 ETDRS letters from baseline over time will be presented.

Up to approximately 96 weeks
Proportion of Participants with BCVA Snellen Equivalent of 20/20 or Better at Week 24
Tidsramme: Week 24

Participants' BCVA in the study eye will be measured using the ETDRS methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity.

The Snellen equivalent of 20/20 or better is defined as ≥84 letters correctly read in the ETDRS chart. The proportion of participants with BCVA Snellen equivalent of 20/20 or better at week 24 will be presented.

Week 24
Proportion of Participants with BCVA Snellen Equivalent of 20/20 or Better Over Time
Tidsramme: Up to approximately 96 weeks

Participants' BCVA in the study eye will be measured using the ETDRS methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity.

The Snellen equivalent of 20/20 or better is defined as ≥84 letters correctly read in the ETDRS chart. The proportion of participants with BCVA Snellen equivalent of 20/20 or better over time will be presented.

Up to approximately 96 weeks
Proportion of Participants with BCVA Snellen Equivalent of 20/40 or Better at Week 24
Tidsramme: Week 24

Participants' BCVA in the study eye will be measured using the ETDRS methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity.

The Snellen equivalent of 20/40 or better is defined as ≥70 letters correctly read in the ETDRS chart. The proportion of participants with BCVA Snellen equivalent of 20/40 or better at week 24 will be presented.

Week 24
Proportion of Participants with BCVA Snellen Equivalent of 20/40 or Better Over Time
Tidsramme: Up to approximately 96 weeks

Participants' BCVA in the study eye will be measured using the ETDRS methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity.

The Snellen equivalent of 20/40 or better is defined as ≥70 letters correctly read in the ETDRS chart. The proportion of participants with BCVA Snellen equivalent of 20/40 or better over time will be presented.

Up to approximately 96 weeks
Proportion of Participants with BCVA Snellen Equivalent of 20/200 or Worse at Week 24
Tidsramme: Week 24

Participants' BCVA in the study eye will be measured using the ETDRS methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity.

The Snellen equivalent of 20/200 or worse is defined as ≤38 letters correctly read in the ETDRS chart. The proportion of participants with BCVA Snellen equivalent of 20/200 or worse at week 24 will be presented.

Week 24
Proportion of Participants with BCVA Snellen Equivalent of 20/200 or Worse Over Time
Tidsramme: Up to approximately 96 weeks

Participants' BCVA in the study eye will be measured using the ETDRS methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity.

The Snellen equivalent of 20/200 or worse is defined as ≤38 letters correctly read in the ETDRS chart. The proportion of participants with BCVA Snellen equivalent of 20/200 or worse over time will be presented.

Up to approximately 96 weeks
Change in National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) Version Composite Score Over Time
Tidsramme: Up to approximately 96 weeks

The NEI-VFQ-25 is a validated and reliable 25-item survey that measures the influence of visual disability and visual symptoms on generic health domains (emotional well-being, social functioning and task-oriented domains). The composite score ranges from 0-100 with the higher score indicating better visual function. The change in NEI-VFQ-25 version composite score over time will be presented.

Up to approximately 96 weeks
Number of Participants who Experience a Systemic Adverse Event (AE)
Tidsramme: Up to approximately 96 weeks

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience a systemic AE will be presented.

Up to approximately 96 weeks
Number of Participants who Experience an Ocular Adverse Event (AE)
Tidsramme: Up to approximately 96 weeks

An ocular adverse event (OAE) is defined as any untoward medical occurrence involving the eye or ocular adnexa (including eyelids, conjunctiva, lacrimal apparatus, extraocular muscles, and orbit) that:

Occurs or worsens after the first administration of the investigational product (IP) or a study-related ocular procedure, and does not necessarily have a causal relationship with the IP or procedure.

OAEs include, but are not limited to, changes in: Symptoms (e.g., ocular pain, photophobia, floaters, blurred vision), Visual function (e.g., best-corrected visual acuity [BCVA], visual field). Intraocular pressure (IOP), Anterior segment findings (e.g., conjunctival hyperemia, keratitis, anterior chamber inflammation), Posterior segment findings (e.g., vitreous inflammation, retinal hemorrhages, retinal tears or detachment, macular edema), or ocular adnexa (e.g., eyelid edema, ptosis). The number of participants who experience an ocular AE will be presented.

Up to approximately 96 weeks
Number of Participants who Discontinue Study Treatment Due to an AE
Tidsramme: Up to approximately 96 weeks

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study treatment due to an AE will be reported.

Up to approximately 96 weeks
Number of Participants with Antidrug Antibodies (ADA) to MK-8748
Tidsramme: At designated time points (up to approximately 96 weeks)

Blood samples collected at designated timepoints will be used to determine the ADA response to MK-8748. The number of participants with ADA to MK-8748 will be presented.

At designated time points (up to approximately 96 weeks)
Maximum Plasma Concentration (Cmax) of MK-8748
Tidsramme: At designated time points (up to approximately 96 weeks)

Cmax is defined as the peak concentration over the dosing interval. Blood samples collected pre-dose and at multiple timepoints post-dose will be used to determine Cmax of MK-8748.

At designated time points (up to approximately 96 weeks)
Plasma Trough Concentration (Ctrough) of MK-8748
Tidsramme: At designated time points (up to approximately 96 weeks)

Ctrough is defined as the trough concentration. Blood samples collected pre-dose and at multiple timepoints post-dose will be used to determine Ctrough of MK-8748.

At designated time points (up to approximately 96 weeks)

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Studieleder: Medical Director, Merck Sharp & Dohme LLC

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

21. desember 2026

Primær fullføring (Antatt)

19. november 2029

Studiet fullført (Antatt)

19. november 2029

Datoer for studieregistrering

Først innsendt

16. november 2026

Først innsendt som oppfylte QC-kriteriene

16. november 2026

Først lagt ut (Faktiske)

20. november 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

20. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

16. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • 8748-006
  • U1111-1342-5647 (Registeridentifikator: UTN)
  • 2026-527378-35-00 (Registeridentifikator: EU CT)
  • MK-8748-006 (Annen identifikator: MSD)

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere